This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Not for use in diagnostic procedures. “We Ballakur added, “It gives them the features they need to scale their use of AI-enabled pathology and capitalize on the latest innovations that shape our understanding of disease.” Concentriq AP is for research use only. Today’s news comes on the heels of a series of announcements from Proscia.
Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceuticaldiagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital.
Telix Pharmaceuticals has selected Cardinal Health to distribute its PET agent TLX250-CDx (Zircaix) for imaging kidney cancer in the U.S., In a recent phase III trial , the radiotracer was shown to be safe and effective for identifying small lesions, which could allow for earlier diagnosis of the disease. the company noted.
milla1cf Tue, 07/25/2023 - 20:22 July 25, 2023 — Ratio Therapeutics Inc. By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers.
produced, non-uranium based Mo-99 for use in diagnostic imaging. These capabilities will help them develop and deliver products with the potential to improve care for even more patients with serious disease. “In Our track record of success includes our program to supply U.S.-produced,
a clinical-stage biotech developing groundbreaking secretome therapeutics for age and disease-related immune dysfunction, has announced a partnership with Springbok Analytics , a life sciences muscle analytics company. christine.book Thu, 07/25/2024 - 12:44 July 25, 2024 — Immunis, Inc. ,
announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceuticaldiagnostics, and digital portfolio. This includes MIMneuro , which offers quantification solutions for dopamine transporter imaging and amyloid imaging.
Currently, when treating metastatic breast cancer patients, oncologists base clinical decisions on diagnostic tools including biopsy results which only represent the sampled area of the tumor. In the U.S.,
In-Med is supported by seed funding from Sriram Natarajan, Founder & CEO of Molbio Diagnostics. The segmentation analysis revealed remarkable accuracy, reliability, and effectiveness of NeuroShield. Globally, over a billion people suffer from neurodegenerative disorders.
We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By milla1cf Tue, 07/11/2023 - 09:02 July 11, 2023 — Ratio Therapeutics Inc.
The rise of precision medicine is putting new pressures on diagnostic laboratories to tap into their pathology data, as whole slide images are among the best representations of disease. The same spatial mapping will also enable Nucleai’s applications to serve as companion diagnostics that match patients to the most effective treatment.
Imagine going in for a diagnostic MRI scan and coming out with a progressive, irreversible, and potentially fatal disease. It certainly doesn't help matters that the disease has been linked to gadolinium-based contrast agents, a ubiquitous tool in the MR armamentarium. In 2006 the U.S. Louis hospital.
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology.
milla1cf Fri, 06/21/2024 - 20:24 June 21, 2024 — GE HealthCare , a leading global medical technology, pharmaceuticaldiagnostics, and digital solutions innovator, and MediView XR Inc.,
For those unfamiliar with steatotic liver disease, this is important because Rezdiffra is the first approved treatment for MASH, which if left untreated can progress to cirrhosis, require liver transplantation, and potentially cause death. Rajarshi Banerjee, MD, PhD.
ii More information: www.bracco.com VUEWAY injection is now available to order from Bracco Diagnostics Inc. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. Manufactured for Bracco Diagnostics Inc. NJ: Bracco Diagnostics Inc.;
History of liver disease, history of substance abuse disorder, and history of delirium tremens were also extracted from the hospital EMR. CIWA scores or some other more universal diagnostic tool for alcohol withdrawal were not routinely used s o we have no idea why one patient got more than another.
The research will produce technical feedback to assist GEHC in assessing the system’s reconstruction methods, image presentation workflow, and clinical benefits for specific pathologies and disease types. MRI GEHC unveiled Signa Champion, a 1.5-tesla,
milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.
The recommendation was issued by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), the primary body in the European Union responsible for regulating pharmaceuticals. The PRAC noted that no clinical diseases or even symptoms have been reported in connection with gadolinium deposition.
Also, the new online pharmaceutical retail industry is gradually penetrating the market. MRI scans offer many applications in the disease diagnosis like neuroscans, liver scans and cardiac. Further advancements in technology related to MRI have widened its scope to diagnose various diseases.
Proscia’s Concentriq AP-Dx is a comprehensive diagnostic software solution that immerses pathologists in an intuitive experience for viewing, interpreting, and managing whole slide images and helps to drive confidence and efficiency gains. Up to 70% of clinical decisions depend on pathology 1. Reference: 1. NHS England (2017).
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content